Human MPO Knockout Cell Line-MOLM13
Cat.No. : CSC-RT2791
Host Cell: MOLM-13 Target Gene: MPO
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2791 |
| Cell Line Information | This cell is a stable cell line with a homozygous knockout of human MPO using CRISPR/Cas9. |
| Target Gene | MPO |
| Host Cell | MOLM-13 |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
Myeloperoxidase (MPO) is located on human chromosome 17 and contains multiple exons and introns. The protein product of the MPO gene is initially synthesized as an inactive precursor called preproMPO, which undergoes several post-translational modifications to become the active enzyme found in the azurophilic granules of neutrophils. These modifications include cleavage of the signal peptide, glycosylation, and subsequent conversion to a mature tetramer consisting of two heavy chains and two light chains. Myeloperoxidase catalyzes the production of hypochlorous acid (HOCl) and other reactive oxygen species during the respiratory burst, which are potent antimicrobial agents capable of destroying a wide range of pathogens, including bacteria, viruses, and fungi.
Mutations and polymorphisms in the MPO gene can have significant effects on human health. For example, certain single nucleotide polymorphisms (SNPs) in the MPO gene have been associated with various diseases, including cardiovascular disease, inflammatory diseases, and certain types of cancer. Although rare, a lack of MPO enzyme activity results in a condition called myeloperoxidase deficiency, which impairs the immune system's ability to fight off infection.
Cancer Research: The MOLM13 cell line, engineered to knock out the MPO gene, is widely used in the study of acute myeloid leukemia (AML). Researchers use this cell line to understand the role of MPO in leukemogenesis and to develop targeted therapies.
Drug Development: This cell line facilitates high-throughput screening of new anticancer agents. By testing drug efficacy and toxicity on MOLM13 MPO knockout cells, promising compounds for further development can be identified.
Gene Function Studies: Knockout of the MPO gene allows scientists to study its function and downstream biological effects. This allows for a better understanding of molecular pathways involved in disease and normal cellular processes.
Biological Pathway Analysis: Researchers use the MOLM13 cell line to study signaling pathways affected by MPO loss. This helps to elucidate new therapeutic targets and understand the complex network of interactions in leukemia cells.
Toxicology Studies: This cell line is used to study the toxicological effects of various compounds in a controlled environment. Understanding how MPO deficiency affects cell viability and response to toxins is critical to developing safer drugs.
For research use only. Not intended for any clinical use.
